(-)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders
US6197788A · kind A · utility
19Cited by
9References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 27, 1999 |
| Grant date | Mar 6, 2001 |
| Priority date | — |
| Expiry date | Sep 27, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/4709
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of (.+-.)-R*,S*)-alpha-2-piperidnyl-2,8-bis(trifluoromethyl)-4-quinolinemthan ol and in particular (-)-(11S,2'R)-alpha-2-piperidnyl-2,8-bis(trifluoromethyl)-4-quinolinemthan ol in the treatment of disorders in which the reduction of purinergic neurotransmission could be beneficial. The invention relates in particular to adenosine receptors, and particularly adenosine A2a receptors and to the treatment of movement disorders such as Parkinson's disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.